MARKET

TMBR

TMBR

Timber Pharmaceuticals Inc
AMEX
1.580
+0.130
+8.97%
Closed 19:43 12/01 EST
OPEN
1.440
PREV CLOSE
1.450
HIGH
1.710
LOW
1.420
VOLUME
316.07K
TURNOVER
--
52 WEEK HIGH
23.22
52 WEEK LOW
1.320
MARKET CAP
4.63M
P/E (TTM)
-0.1130
1D
5D
1M
3M
1Y
5Y
BRIEF-Timber Pharmaceuticals Provides Business Update, Announces Q3 Financial Results
Reuters · 11/14 18:16
Timber Pharmaceuticals GAAP EPS of -$1.52
Seekingalpha · 11/14 13:50
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results
-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial continues to progress; expected to enroll more than 140 patients with moderate to severe Congenital Ichthyosis- ...
GlobeNewswire · 11/14 13:00
Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 11/09 17:33
Timber Pharmaceuticals Announces 1-For-50 Reverse Stock Split
Benzinga · 11/08 17:12
Timber Pharmaceuticals to Effect 1-for-50 Reverse Stock Split
Timber Pharmaceuticals to Effect 1-for-50 Reverse Stock Split
MT Newswires · 11/08 14:01
BRIEF-Timber Pharmaceuticals Announces Halt of Common Stock Trading
Reuters · 11/03 12:49
Timber Pharmaceuticals Announces Halt Of Common Stock Trading On NYSE Due To Low Trading Price Of Shares On November 1; Co. Expects Halt To Remain in Effect Until After Timber's Special Meeting Of Stockholders Scheduled For November 7
Benzinga · 11/03 12:26
More
About TMBR
Timber Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of treatments for orphan dermatologic diseases. It is also focused on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis (CI), facial angiofibromas (FAs) in the tuberous sclerosis complex (TSC), and sclerotic skin diseases. Its lead mid to late-stage programs are TMB-001 and TMB-002. TMB-003 is its earliest stage program. TMB-001 is a topical formulation of isotretinoin using its IPEG delivery system, completed its Phase IIb clinical trials for the treatment of moderate to severe subtypes of CI. TMB-002 is a topical formulation of rapamycin, which is being evaluated in a Phase IIb clinical trial for the treatment of FAs in TSC. TMB-003 is a formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist for the treatment of sclerotic skin diseases.

Webull offers kinds of Timber Pharmaceuticals Inc stock information, including AMEX:TMBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TMBR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TMBR stock methods without spending real money on the virtual paper trading platform.